7 Undervalued Pharmaceuticals Stocks for Friday, October 11
Discover the top 7 undervalued Pharmaceuticals stocks for Friday, October 11 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Commentary & Analysis
5 Undervalued Biotechnology & Medical Research Stocks for Wednesday, May 08
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Wednesday, May 08 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Biotechnology & Medical Research Stocks for Tuesday, December 26
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Tuesday, December 26 based on AAII’s Stock Grades.Grace Malone
4 Undervalued Biotechnology & Medical Research Stocks for Monday, September 04
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Monday, September 04 based on AAII’s Stock Grades.Eunice Kim
5 Undervalued Biotechnology & Medical Research Stocks for Wednesday, July 26
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Wednesday, July 26 based on AAII’s Stock Grades.Grace Malone
Financial Summary
| Share Statistics | PULM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.5 | $618.0 | 3% |
|
| Shares Out (Mil) | 3.7 | 44.8 | 11% |
|
| Institutional Ownership | na | 85.3% | na |
|
| Float (Mil) | 3.7 | 47.4 | 9% |
|
| Beta | 1.92 | 0.70 | 92% |
|
| Avg Daily Volume (000s) | 11 | 390 | 17% |
|
| Price Change (52-week) |
(68.2%) | 68.6% | 9% |
|
| Growth | PULM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 23.1% | (1.6%) | 77% |
|
| EPS (5yr) | 36.3% | 14.9% | 86 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.7%) | (14.9%) | 39% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PULM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($4) | ($11) | 34% |
|
| EPS (TTM) | ($1.103) | ($0.700) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($6) | 26% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $4 | $450 | 5% |
|
| Valuation | PULM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.41 | 2.78 | 68% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PULM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (85.4%) | (22.4%) | 6% |
|
| ROE | (111.5%) | (20.2%) | 8% |
|
| Liabilities to Assets | 21.2% | 32.2% | 14% |
|
| F-Score | 2 | 3 | 7% |
|
Pulmatrix, Inc. did not pass any screens on 8/20/2026.
